Fresenius Medical Care reports Q3 results and lowers 2026 outlook
On November 3, 2026, Fresenius Medical Care reported Q3 revenue of EUR 4,937 million, up 1% year over year, while reported operating income fell 19% and reported net income fell 42% to EUR 160 million. The company said one-time China strategy costs drove much of the net-income decline, while adjusted EPS remained stable. It now expects 2026 revenue to be broadly flat and operating-income growth, at constant currency and excluding special items, between flat and a negative mid-single-digit percentage rate.
Why it matters
The lower operating-income outlook reduces the expected earnings range for Fresenius Medical Care and reflects regulatory, inflation and fourth-quarter pressures. The company also expects TDAPA-related operating-income pressure of EUR 300 million to EUR 350 million in 2027, according to its earnings-call commentary.
Key facts
- 1Q3 revenue was EUR 4,937 million versus EUR 4,885 million a year earlier, a 1% year-over-year increase. prnewswire.com
- 2Reported Q3 operating income declined 19% to EUR 384 million, while operating income excluding special items declined 5% to EUR 545 million. prnewswire.com
- 3Q3 reported net income decreased 42% to EUR 160 million, while net income excluding special items fell 10% to EUR 291 million. prnewswire.com
- 4Fresenius Medical Care converted 348 U.S. clinics, representing 16% of its U.S. dialysis machines, to the 5008X CAREsystem and recorded 1.3 million treatments. prnewswire.com
- 5The company said its 2026 operating-income outlook now ranges from flat to a negative mid-single-digit percentage growth rate, on a constant-currency basis and excluding special items. prnewswire.com
- 6Management expects TDAPA-related operating-income pressure of EUR 300 million to EUR 350 million in 2027 compared with 2026. finance.yahoo.com
Open questions
- attributes EUR 108M of one-time costs to China, while the primary release and earnings-call material do not provide that same China-cost figure separately.
- reports ADR EPS of $1.26 and revenue of $5.6B, but does not provide a clearly aligned basis with the EUR-denominated figures in the primary earnings release.
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.